Skip to content
Macrophage PharmaMacrophage Pharma
Macrophage Pharma Appoints Dr Venkat Reddy as Chief Executive Officer
1 June 2021

Executive leadership and strategic focus strengthened for sustained company development [...]

Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer
9 January 2020

Key hires enhance management for next development phase [...]

Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors
29 September 2019

Appointment widens industry leadership perspective, translational and commercial expertise [...]

Macrophage Pharma Appoints Dr Søren Bregenholt as Chief Executive Officer
3 September 2019

Strategic and operational leadership expanded for progressing broad pipeline [...]

Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board
10 September 2018

Formation of an international Scientific Advisory Board (SAB). [...]

Macrophage Pharma Appoints Dr Michael Moore as Chairman
11 April 2018

Has appointed Dr. Michael Moore as non-executive Chairman with immediate effect. [...]

Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference
7 November 2017

Two abstracts will be presented on its proprietary Esterase Sensitive Motif™ (ESM™) technology [...]

Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures
23 August 2017

Merck Ventures Joins Investment Syndicate and the Board of Macrophage [...]

  • About
  • Science
  • News & Views
  • Contact

© Copyright 2021 Macrophage Pharma. All rights reserved.
Privacy Notice | Cookie Policy

Stephen Cork and Anthony Cork of Cork Gully LLP have been appointed to act as Joint Administrators of Macrophage Pharma Limited (in Administration) (“the Company”) on 9 February 2022.
The business and affairs of the Company will now be managed by the Joint Administrators and their staff.

In the event that you have any immediate queries in respect of the Company position please contact Darren Habgood on +44 (0) 20 7268 2150.

Copyright 2023 © Flatsome Theme
  • About
  • Science
  • News & Views
  • Contact
DAVID MOFFAT, PHD CCHEM FRSC

Dr Moffat joined Macrophage Pharma in November 2014. He had previously been Director of Chemistry at Chroma Therapeutics from 2004 to 2012 having played a leading role in the discovery and development of the Esterase Sensitive Motif technology platform. During this period three molecules from his chemistry team were progressed to the clinic including the macrophage targeted histone deacetylase inhibitors CHR-2845 and CHR-5154. His was also Head of Chemistry at Celltech from 2001 to 2004, prior to its acquisition by UCB, having begun his industrial career there in 1989.

He holds a BSc and PhD from the University of Glasgow. He has extensive experience in oncology and inflammation preclinical research, having led groups which have identified numerous clinical development candidates in these therapeutic areas. He is the author and inventor on more than 60 patents and publications.